The Symptomatic Cerebral Cavernous Malformation Trial of REC-994 — SYCAMORE

Cerebral Cavernous Malformation Clinical Trial

Official title:
A Two-Part Study of REC-994 in the Treatment of Adults With Symptomatic Cerebral Cavernous Malformation (CCM); Part 1: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Efficacy and Pharmacokinetics of Two Doses of REC-994; Part 2: A Long-Term Blinded Extension Clinical Trial to Evaluate Long-Term Safety Tolerability and Efficacy of REC-994

Status Active, not recruiting

Clinical Trial Summary

This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, efficacy and pharmacokinetics of REC-994 (200 mg and 400 mg) compared to placebo in subjects with symptomatic cerebral cavernous malformation (CCM).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05085561
Study type	Interventional
Source	Recursion Pharmaceuticals Inc.
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	March 17, 2022
Completion date	December 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04467489` - Biomarkers of CASH
Active, not recruiting	`NCT02946866` - CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
Recruiting	`NCT05298709` - Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)	N/A
Active, not recruiting	`NCT02603328` - Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial	Phase 1/Phase 2
Terminated	`NCT05148663` - CCM Blood Biomarker Validation Study
Completed	`NCT03652181` - CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Completed	`NCT03589014` - Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation	Phase 2